12 June 2018 - - Cambridge, Massachusetts-based biotechnology company Generation Bio has appointed Jeff Jonas, M.D., chief executive officer of Sage Therapeutics, to its board of directors, the company said.
Jonas joined Sage in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries including several executive and senior-level positions at companies including Shire, Isis Pharmaceuticals, Forest Laboratories, and Upjohn. He also founded Avax Technologies and Sceptor Industries.
Jonas has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.
He received his B.A. from Amherst College and M.D. from Harvard Medical School with a residency in psychiatry at Harvard and then chief resident in psychopharmacology at McLean Hospital, Harvard Medical School.
Generation Bio is developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease.
The company's therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime.